TRISTEL plc
("Tristel" or the
"Company")
Notice of Preliminary
Results
Investor presentations
Tristel plc (AIM: TSTL), the manufacturer of
infection prevention products, announces that its preliminary
results for the year ended 30 June 2024 will be announced on Monday
21 October 2024.
Analyst briefing
A briefing open to analysts will
take place in London on Monday 21 October 2024
at 10:00 BST. To register and for more details
please contact Walbrook PR on tristel@walbrookpr.com
Investor
presentations
Matt Sassone, CEO, and Liz Dixon, CFO, will
present the Company's results in two separate events open to all
investors. The same presentation will be given at both events which
are being held at different times to offer convenient options for
those wishing to attend.
Two presentations will take place on
Monday 21 October 2024 at the following times,
the first will be held online via the Investor Meet Company
platform and the second will be held in-person in the City of
London, full details below:
1. Investor Meet
Company online presentation
Tristel management will provide a
live online presentation relating to the preliminary results
via Investor Meet Company at 11:30 BST. The presentation is open to
all existing and potential shareholders. Questions can be submitted
pre-event via your Investor Meet Company dashboard up until 09:00
BST the day before the meeting or at any time during the live
presentation.
Investors can sign up to Investor
Meet Company for free and add to meet Tristel
plc via:
https://www.investormeetcompany.com/tristel-plc/register-investor
2. In-person investor
presentation
Tristel management will provide an
in-person presentation relating to the
Company's preliminary results at 16:30 BST, which is open to all
existing and potential shareholders. The
Company welcomes investors to 85 Gresham Street, London, EC2V
7NQ from 16:15
BST for a 16:30 BST start and will be followed by
refreshments.
If you would like to attend, please
contact Walbrook PR on 020 7933 8780 or
email tristel@walbrookpr.com.
The results presentation will be
made available on the Company's website on the day of
results www.investors.tristel.com
For further
information please contact:
|
Tristel plc
|
Via
Walbrook PR
|
|
Matt Sassone, Chief Executive
Officer
|
www.investors.tristel.com
|
|
Liz Dixon, Chief Financial
Officer
|
|
|
|
|
|
Walbrook PR Ltd
|
Tel:
02079338780 or tristel@walbrookpr.com
|
|
Paul McManus / Alice
Woodings
|
Mob: 07980
541 893 / 07407 804
654
|
|
|
|
|
Cavendish Capital Markets Ltd
|
Tel: 020
7220 0500
|
|
Geoff Nash / Camilla Hume / Trisyia
Jamaludin (Corporate Finance)
|
|
|
Sunila de Silva (ECM) / Louise
Talbot (Sales)
|
|
About Tristel
plc
Tristel plc is a global infection
prevention company focussed on the manufacture and supply of
products using its unique proprietary chlorine dioxide
(ClO2) chemistry. The Company is a market leader
in manual decontamination of medical devices, supplying
hospitals under the Tristel brand, and under the
Cache brand provides
products for sporicidal surface disinfection, a more sustainable
alternative to commonly used pre-wetted plastic wipes.
Tristel's head office and manufacturing
facility is located in Snailwell, near Cambridge, and operates
globally employing approximately 250 people across 14 subsidiaries
selling into 40 countries. The Company targets annual revenue
growth of between 10% and 15% and an EBITDA margin of at least 25%
(targets to be updated in February 2024) and the business is
profitable, with no debt and has a progressive dividend
policy.
The Company has been listed on the London Stock
Exchange's AIM market since 2005 (AIM: TSTL).
For more information about Tristel's product
range please visit: https://tristel.com